Evaluation and Treatment of Obesity in Primary Care
This chapter reviews the results of randomized trials of the treatment of obesity in primary care. The results are described in the context of the recent decision by CMS (Center for Medicare and Medicaid Services) to reimburse primary care providers for a schedule of visits that meets criteria for high-intensity obesity treatment, as is recommended by the US Preventive Services Task Force. We found that trials in which counseling was provided by PCPs themselves or other office staff typically led to modest weight loss (1–3 kg), likely a result of low-to-moderate-intensity intervention. Trials that provided multimodality treatment, combining counseling with pharmacotherapy or meal replacements, more often achieved clinically significant weight loss (≥5 % of starting weight). Remotely delivered interventions (telephone and web-based) yielded modest weight loss in two studies involving low-income populations, but produced higher weight losses in two trials involving more socioeconomically diverse populations. In the single trial that most closely approximated the schedule of visits currently reimbursed by CMS, dietitians as counselors achieved more than twice the weight loss achieved by PCPs (with patients using meal replacements in both groups). Further study is needed to determine how best to deliver high-intensity counseling to obese patients in primary care settings, including economic analyses to determine the most efficient ways to offer treatment.
KeywordsUsual Care Primary Care Setting Primary Care Practice Weight Loss Program Obesity Treatment
Preparation of this article was supported, in part, by grant K24-DK065018 from the National Institute of Diabetes Digestive and Kidney Disease, grant U01-HL087072 from the National Heart, Lung, and Blood Institute, and grant 10SDG2610292 from the American Heart Association.
Thomas Wadden serves on advisory boards for Novo Nordisk and Orexigen Therapeutics, each of which is developing weight loss medications. None of the other authors has any potential conflicts of interest to disclose.
- 2.Center for Medicare and Medicaid Services. Decision memo for intensive behavioral therapy for obesity (CAG-00423N). 2011. http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?&NcaName=IntensiveBehavioralTherapyforObesity&bc=ACAAAAAAIAAA&NCAId=253&. Accessed 10 Dec 2011.
- 4.National Heart Lung and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. National Institutes of Health. Obesity Res. 1998;6 Suppl 2:51S–209.Google Scholar
- 12.National Heart Lung and Blood Institute (NHLBI) and North American Association for the Study of Obesity (NAASO). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication 02-4084; 2000.Google Scholar
- 15.Wing R. Behavioral treatment of obesity. In: Wadden TA, Stunkard AJ, editors. Handbook of obesity treatment. New York: Guilford; 2002. p. 301–16.Google Scholar
- 23.Tsai AG, Fabricatore AN, Wadden TA, et al. Readiness redefined: a behavioral task during screening predicted 1-year weight loss in the Look AHEAD study. Obesity. 2014;22(4):1016–23.Google Scholar
- 34.Ockene IS, Hebert JR, Ockene JK, et al. Effect of physician-delivered nutrition counseling training and an office-support program on saturated fat intake, weight, and serum lipid measurements in a hyperlipidemic population: Worcester Area Trial for Counseling in Hyperlipidemia (WATCH). Arch Intern Med. 1999;159(7):725–31.PubMedCrossRefGoogle Scholar
- 40.Brownell KD. The LEARN program for weight control: lifestyle, exercise, attitudes, relationships, nutrition. Dallas: American Health Publishing; 1998.Google Scholar
- 46.Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.PubMedCentralPubMedCrossRefGoogle Scholar
- 50.Ma J, Yank V, Xiao L, et al. Translating the Diabetes Prevention Program lifestyle intervention for weight loss into primary care: a randomized trial. JAMA. 2013;173(2):113–21.Google Scholar
- 81.McQuigg M, Brown J, Broom J, et al. Empowering primary care to tackle the obesity epidemic: the Counterweight Programme. Eur J Clin Nutr. 2005;59 Suppl 1:S93–100; discussion S101.Google Scholar